EN DE
Watch Capricor Therapeutics Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Capricor Therapeutics Inc (CAPR) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Capricor Therapeutics Inc stock $5.35, price $7.59, that is 29.5% below the price, quality 23 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CT Capricor Therapeutics Inc logo Thin data Nov 21, 2026

Capricor Therapeutics Inc

CAPR · US

Expensive (fair value 30% below the price) and weak company, but rising price: meets 1 of 3 rules.

Follow free in the weekly email
Rising price (uptrend) 
Low debt 
Mixed Growth (revenue 5y +85.8 %/yr in USD) 
Insiders sold $1.5M (6M) 
Fair value $5.35 · Overvalued 
Quality 23/100 
Negative free cash flow 
Trails peers (3/9) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Capricor Therapeutics Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$35.34 $2.71 Fair Value $5.35 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 21, 2026.

How to read this chart

60‑month range $2.71 – $35.34 · fair‑value band $4.01 – $6.69 · the $7.59 price screens above the $5.35 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 21, 2026.

Follow Capricor Therapeutics in your weekly email

Every Wednesday you see whether Capricor Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Show moreShow less

Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial.

In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform.

The company was founded in 2005 and is headquartered in San Diego, California.

Stock analysis

Capricor Therapeutics Inc (CAPR) currently trades at $7.59, while our estimate is $5.35, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $4.01 (bear) to $6.69 (bull), the price of $7.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2017: revenue and profit before it include the divested business. Growth is measured afresh from 2017.

Capricor Therapeutics Inc reported revenue of $0 in FY2025 versus $245K in FY2021. Reported net income was −$105M in FY2025.

Key figures

Market cap $595M Small · P/S ratio 53.5 · EPS (TTM) $-2.65 · Return on equity −100% · Return on assets (EBIT) −41.3% (5-year average) · Revenue (TTM) $11.1M · Revenue growth (quarter YoY) −7.9% · Free cash flow −$72.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 79% below its 52-week high and 97% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −30%, CAPR screens richer than that median.

Fair Value

Bear $4.01 Fair Value $5.35 Bull $6.69
Price $7.59 · Downside -29.5%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 23/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 40
How calm the share price moves, does not count
Price momentum 36
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 40
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $1.5M and none bought.

  • SaleKaren KrasneyEVP, GENERAL COUNSEL4× since Mar 31, 2026: 75,000 shares, avg. $30.73$2.3MJun 25, 202610b5-1 plan
  • SaleAnthony BergmannCHIEF FINANCIAL OFFICER4× since Mar 31, 2026: 75,000 shares, avg. $30.73$2.3MJun 25, 202610b5-1 plan
  • SaleKarimah Es SabarDirector2× since Mar 31, 2026: 122,529 shares, avg. $30.66$3.8MApr 2, 202610b5-1 plan

Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 20, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2017: revenue and profit before it include the divested business. Growth is measured afresh from 2017.
Revenue growth 1 year
−11.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+349.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+85.8%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−769.5% (2019) → −191.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CAPR screens overvalued: fair value 30% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Capricor Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 854 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 23 · Bottom 25%
Fair Value upside −29.5% · Below median
Profitability
Return on assets −29.5% · Below median
Growth and dividend
Revenue growth (quarter YoY) −7.9% · Below median
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.95× · Cheaper than median
P/S (12 months) 53.49× · Priciest 25%
PEG 0.38× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 32
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $920.69 $1,275.02 +38% vs CAPR
Vertex Pharmaceuticals Incorporated VRTX $515.02 $566.52 +10% vs CAPR
Samsung Biologics Co 207940 ₩1,355,000 ₩1,490,500 +10% vs CAPR
argenx SE ARGX $925.70 $908.40 −2% vs CAPR
CSL Limited CSL A$197.29 A$188.80 −4% vs CAPR
BeOne Medicines AG 6160 HK$230.80 HK$152.92 −34% vs CAPR
Moderna, Inc MRNA $195.00 $119.97 −38% vs CAPR
Revolution Medicines, Inc RVMD $161.20 $83.14 −48% vs CAPR
Celltrion, Inc 068270 ₩213,000 ₩74,574 −65% vs CAPR
Royalty Pharma plc RPRX $68.45 $19.01 −72% vs CAPR

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Capricor Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Capricor Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/CAPR

Frequently asked questions

Is Capricor Therapeutics Inc (CAPR) overvalued or undervalued?
As of Nov 21, 2026, our estimate of fair value is $5.35 versus a price of $7.59, about 30% lower (overvalued).
What is the fair value of CAPR?
Our estimate for Capricor Therapeutics Inc is $5.35 (as of Nov 21, 2026), built from audited fundamentals. The current price: $7.59.
What is the quality score of CAPR?
Capricor Therapeutics Inc has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Capricor Therapeutics Inc (CAPR)?
We do not set a price target; the yardstick is our estimate of $5.35 (as of Nov 21, 2026). Cautious scenario $4.01, optimistic scenario $6.69. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Capricor Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $5.35, about 30% lower versus a price of $7.59 (overvalued). Cautious scenario $4.01, optimistic scenario $6.69. The calculation is refreshed regularly with new filings.
What is the revenue of Capricor Therapeutics Inc (CAPR)?
Capricor Therapeutics Inc reported trailing-twelve-month revenue of about $11.1M (latest available figure, as of Nov 21, 2026).
What is the intrinsic value of Capricor Therapeutics Inc (CAPR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Capricor Therapeutics Inc it is $5.35 per share (as of Nov 21, 2026), against a price of $7.59.
Is Capricor Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 21, 2026, CAPR trades above its calculated fair value: price $7.59, fair value $5.35, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CAPR?
No. The price is what the market pays today ($7.59); the fair value is what the company's own numbers justify ($5.35). For Capricor Therapeutics Inc the two are $2.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is Capricor Therapeutics Inc worth?
The market values Capricor Therapeutics Inc at about $595M (market capitalisation, as of Nov 21, 2026). Per share that is $7.59; our models calculate a fair value of $5.35 per share.
What do the bullish and bearish scenarios say about CAPR?
Our models span a range for Capricor Therapeutics Inc: cautious scenario $4.01, base $5.35, optimistic $6.69 per share (as of Nov 21, 2026, price $7.59). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of CAPR?
The PEG ratio of Capricor Therapeutics Inc is 0.38 (P/E divided by earnings growth, as of Nov 21, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Capricor Therapeutics Inc (CAPR)?
Balance-sheet figures for Capricor Therapeutics Inc (as of Nov 21, 2026): return on equity −100.5%, debt of 0.01 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is CAPR from its 52-week high?
Capricor Therapeutics Inc trades at $7.59, about 79% below its 52-week high of $35.34 and 97% above the low of $3.85 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of $5.35 is for.
Which stocks are comparable to Capricor Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Capricor Therapeutics Inc stock attractive at the current price?
The data as of Nov 21, 2026: price $7.59, calculated fair value $5.35 (−30%), Quality Score 23/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Capricor Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Capricor Therapeutics Inc (CAPR)?
The closing price on Nov 20, 2026 was $7.59. Our estimate is $5.35, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Capricor Therapeutics Inc right now?
The price sits above even our optimistic bull case ($6.69). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Capricor Therapeutics Inc

How large is the market capitalisation of Capricor Therapeutics Inc (CAPR)?
The market capitalisation of Capricor Therapeutics Inc is $595M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Capricor Therapeutics Inc (CAPR)?
The price-to-sales ratio of Capricor Therapeutics Inc is 53.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Capricor Therapeutics Inc (CAPR)?
Earnings per share at Capricor Therapeutics Inc are $-2.65. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Capricor Therapeutics Inc (CAPR)?
The return on equity (ROE) of Capricor Therapeutics Inc is −100% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Capricor Therapeutics Inc (CAPR)?
On an EBIT basis the return on assets of Capricor Therapeutics Inc is −41.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Capricor Therapeutics Inc (CAPR)?
Revenue at Capricor Therapeutics Inc is down 7.9% in the last quarter versus the same quarter a year earlier (3y avg +350%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How much free cash flow does Capricor Therapeutics Inc (CAPR) generate?
The free cash flow of Capricor Therapeutics Inc is −$72.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Capricor Therapeutics Inc (CAPR) hold?
Capricor Therapeutics Inc holds more cash than debt, $267M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Capricor Therapeutics Inc in the live analysis

One click puts Capricor Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.